Endocrine Toxicities: Management of irAEs Guideline (Part 6)
An interview with Dr. Jennifer Mammen from Johns Hopkins University, author on "Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline...
5 Marras 202114min
Lung Toxicities: Management of irAEs Guideline (Part 5)
An interview with Dr. Jarushka Naidoo from Johns Hopkins University, author on "Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline...
4 Marras 202110min
Gastrointestinal Toxicities: Management of irAEs Guideline (Part 4)
An interview with Dr. Yinghong Wang from MD Anderson Cancer Center, author on "Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline ...
3 Marras 20218min
Cutaneous Toxicities: Management of irAEs Guideline (Part 3)
An interview with Dr. Milan Anadkat from Washington University & Dr. Aung Naing from MD Anderson Cancer Center, authors on "Management of Immune-Related Adverse Events in Patients Treated With Immune ...
2 Marras 202111min
CAR-T Cell Therapy: Management of irAEs Guideline (Part 2)
An interview with Dr. Bianca Santomasso from Memorial Sloan Kettering Cancer Center and Dr. Monalisa Ghosh from the University of Michigan Health System, authors on "Management of Immune-Related Adver...
1 Marras 202130min
ICPi Overview: Management of irAEs Guideline (Part 1)
An interview with Dr. Bryan Schneider from the University of Michigan Health System and Dr. Kathryn Bollin from Scripps MD Anderson Cancer Center, co-chairs of the Management of Immune-Related Adverse...
1 Marras 202113min
Immunotherapy in Patients with Locally Advanced Esophageal Carcinoma: ASCO Guideline Rapid Recommendation Update
An interview with Dr. Manish Shah from New York Hospital and Weill Cornell Medicine, co-chair on "Immunotherapy in Patients with Locally Advanced Esophageal Carcinoma: ASCO Guideline Rapid Recommendat...
18 Elo 20218min
Adjuvant PARP Inhibitors in Patients with High-risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update
An interview with Dr. Nadine Tung and Dr. Dana Zakalik, co-chairs on "Adjuvant PARP Inhibitors in Patients with High-risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Here...
3 Elo 202115min
